Table 1

Patient demographic and clinical characteristics and indications for voriconazole therapy

VariableNo. of patients (n = 201)
    Age (yr)a54 (18–88)
    Sex, male/female116/85
    Weight (kg)a,b68 (38–113)
Indication for therapyc
    Proven IFI44
    Probable IFI23
    Possible IFI59
    Localized fungal infectiond17
    Empirical therapy27
    Antifungal prophylaxis31
Underlying condition
    Hematological malignancy118
    Solid organ transplantation26
    Diabetes mellitus8
    Myelodysplastic syndrome7
    Other malignancy5
    Vasculitic condition5
    Other conditione18
Site of infectionf
    Skin and soft tissue6
    Invasive sinusitisj4
  • a Median (range).

  • b Weight was available for 187/201 patients.

  • c Defined according to the 2008 EORTC/MSG guidelines (8).

  • d Fungal cellulitis (6 patients), localized eye infection (5 patients), ear infection (4 patients), esophagitis (2 patients).

  • e Chronic lung disease (3 patients), aplastic anemia (2 patients), IgG deficiency (1 patient), severe combined immunodeficiency (1 patient), HIV (1 patient), rheumatoid arthritis (1 patient), systemic lupus erythematosus (1 patient), sarcoidosis (1 patient), scleroderma, Caroli syndrome (1 patient), myasthenia gravis (1 patient), ulcerative colitis (1 patient), long-term corticosteroid use (1 patient), intravenous drug use (1 patient), recent brain surgery (1 patient).

  • f Does not include patients taking voriconazole for antifungal prophylaxis.

  • g Skin and soft tissue involvement (4 patients).

  • h Disseminated infection in 4 patients.

  • i Lung involvement (1 patient).

  • j Lung involvement (1 patient).

  • k Endocarditis (2 patients), liver (2 patients), bloodstream (2 patients), esophagitis (2 patients), osteomyelitis (1 patient).